Lifitegrast sodium (SAR 1118; SHP-606; SAR-1118-023; Xiidra), the sodium salt of Lifitegrast, is an integrin lymphocyte function-associated antigen-1 (LFA-1) antagonist with the potential for Treatment of Dry Eye Disease. It inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. In 2016, Lifitegrast received FDA approval for the treatment of signs and symptoms of dry eye, a syndrome called keratoconjunctivitis sicca. Lifitegrast reduces inflammation by inhibiting inflammatory cell binding.

纯度：≥98%

CAS：1119276-80-0